Core Points - Roche's shareholders approved all proposals from the Board of Directors during the Annual General Meeting, with 77.03% of shares represented [1] - The company reported a significant increase in demand for its innovative diagnostic tests and medicines in 2024, highlighting a successful year [2] - A dividend increase to 9.70 Swiss francs per share was approved, marking the 38th consecutive increase [2][5] - Dr. Severin Schwan was re-elected as Chairman of the Board with 97.93% of votes, and all other Board members were also re-elected [2][3] - The total bonuses for the Corporate Executive Committee for the 2024 financial year were approved by 95.00% of votes [3] Financial and Governance Highlights - The Annual Financial Statements and Consolidated Financial Statements for 2024 were approved by shareholders [1] - Shareholders authorized the discharge of the Board of Directors and the Corporate Executive Committee [2] - KPMG AG was appointed as statutory auditors for the 2025 financial year [4] Strategic Focus - Roche aims to continue its success through expertise in Pharmaceuticals and Diagnostics, innovative technologies, and a promising pipeline [2] - The company is committed to sustainability and aims to achieve net zero by 2045, aligning with the Science Based Targets initiative [8]
Roche Annual General Meeting 2025